Monte Rosa Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other information
Rule 10b5-1 Trading Plans
During the fiscal quarter ended on March 31, 2026, none of our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act)adopted, modified orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408(a) of Regulation S-K.
| Name and Title | Action | Action Date | Duration of Trading Arrangements | Rule 10b5-1 Trading Arrangement? (Y/N)* | Aggregate Number of Securities Subject to Trading Arrangement |
|---|---|---|---|---|---|
| Jennifer ChampouxChief Operating Officer | Adopt | February 19, 2026 | May 22, 2026 - December 15, 2026 | Y | Up to 30,456 shares of common stock underlying stock options to be sold |
| Sharon TownsonChief Scientific Officer | Adopt | February 27, 2026 | May 29 2026 - January 29, 2027 | Y | Up to 50,000 shares of common stock underlying stock options to be sold |
| Filip JankuChief Medical Officer | Adopt | March 4, 2026 | June 3, 2026 - February 5, 2027 | Y | Up to 74,304 shares of common stock to be sold, consisting of up to 68,459 shares underlying stock options and up to 5,485 shares underlying restricted stock units |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.